Associations between biomarkers at discharge and co-morbidities and risk of readmission after community-acquired pneumonia

Petersen, Pelle Trier; Egelund, Gertrud Baunbæk; Jensen, Andreas Vestergaard; Andersen, Stine Bang; Pedersen, Merete Frejstrup; Rohde, Gernot; Ravn, Pernille

Published in:
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

DOI:
10.1007/s10096-018-3224-8

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Petersen, P. T., Egelund, G. B., Jensen, A. V., Andersen, S. B., Pedersen, M. F., Rohde, G., & Ravn, P. (2018). Associations between biomarkers at discharge and co-morbidities and risk of readmission after community-acquired pneumonia: a retrospective cohort study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 37(6), 1103-1111. https://doi.org/10.1007/s10096-018-3224-8
Associations between biomarkers at discharge and co-morbidities and risk of readmission after community-acquired pneumonia: a retrospective cohort study

Pelle Trier Petersen 1 · Gertrud Baunbæk Egelund 1,2 · Andreas Vestergaard Jensen 1,2 · Stine Bang Andersen 1 · Merete Frejstrup Pedersen 3 · Gernot Rohde 4,5 · Pernille Ravn 6

Received: 12 November 2017 / Accepted: 28 February 2018 / Published online: 29 March 2018
© The Author(s) 2018

Abstract
To investigate whether hemoglobin, white blood cell count (WBC), urea, sodium, albumin, and C-reactive protein at discharge in patients hospitalized for community-acquired pneumonia (CAP) are associated with 30-day readmission. This study is a retrospective cohort study, which included all adult patients discharged after hospitalization for CAP from three Danish hospitals between January 2011 and July 2012. The outcome was all-cause, unplanned, 30-day readmission. Biomarker concentrations at discharge were transformed into binary variables by using either upper or lower quartiles as cut-off; the upper quartile was used for WBC, urea, and C-reactive protein, and the lower quartile was used for hemoglobin, sodium, and albumin. The study population consisted of 1149 patients. One hundred eighty-four (16.0%) patients were readmitted. Independent risk factors of readmission were WBC $\geq 10.6$ cells $\times 10^9$/L (hazard ratio 1.50; 95% CI, 1.07–2.11) and albumin <32 g/L (hazard ratio 1.78; 95% CI, 1.24–2.54) at discharge and the presence of $\geq 2$ co-morbidities (hazard ratio 1.74; 95% CI, 1.15–2.64). When WBC, albumin, and co-morbidities were combined into a risk-stratification tool, there was a step-wise increase in risk of readmission for patients with 1, 2, or 3 risk factors with hazard ratios of 1.76 (95% CI, 1.25–2.49), 2.59 (95% CI, 1.71–3.93), and 6.15 (95% CI 3.33–11.38), respectively. WBC $\geq 10.6$ cells $\times 10^9$/L and albumin < 32 g/L at discharge and the presence of $\geq 2$ co-morbidities were independently associated with increased risk of 30-day readmission.

Keywords Community-acquired pneumonia · Readmission · Risk factor · Biomarker

Introduction
Community-acquired pneumonia (CAP) is a common cause of hospitalization, and with as many as 1 in 5 patients returning to the hospital within 30 days after discharge, readmission is a significant burden to both patients and healthcare systems [1–4].

Readmission may be prevented with post-discharge interventions, but success and cost-effectiveness partly depend on accurate risk-stratification, which again presupposes identification of important risk factors [5, 6]. Risk factors of readmission for patients hospitalized for CAP have not been well described, and previous research has primarily evaluated factors which either pre-exist the pneumonia or reflect the severity at the day of admission [7–12]. Factors, which reflect the cause of hospitalization and the health status at discharge, might, however, be important predictors of readmission [13]. We hypothesized that six different blood-based biomarkers...
routinely measured in patients with CAP would be associated with risk of readmission after hospitalization for CAP and could be used in a risk-stratification tool.

Thus, the objective of this study was to investigate whether hemoglobin, white blood cell count (WBC), urea, sodium, albumin, and C-reactive protein at discharge in patients hospitalized for CAP are associated with 30-day readmission.

Methods

Setting and patients

This study was based on the retrospective CAP-NORTH Cohort, which has previously been described in detail by Egelund et al. [14]. In brief, the CAP-NORTH Cohort was created by evaluating all consecutive patients with an ICD-10 code of pneumonia admitted to three Danish hospitals between January 1, 2011, and July 1, 2012. The inclusion criteria were: at least one symptom of lower respiratory tract infection at admission. Patients with HIV, active tuberculosis, or pharmacological immunosuppression or patients who had been hospitalized within the preceding 28 days of admission were excluded. Patients with more than one admission during the study period were included with reference to the first contact.

In this study, patients who died during the index-hospitalization or had missing data on follow-up or biomarkers at discharge were excluded.

Variables

Information on demographic characteristics, co-morbidities, initial severity of the pneumonia, and the course of index-hospitalization was collected from medical records. The following co-morbidities were registered: chronic obstructive respiratory disease (COPD), other chronic respiratory diseases, malignancy, chronic heart failure, other chronic heart diseases, neurovascular diseases, other chronic neurological diseases, chronic renal failure, chronic liver failure, and diabetes. The combined burden of co-morbidities was assessed by categorizing patients into three groups based on the summarized number of independent risk factors of readmission. Data was censored at 30 days after discharge. In the regression analyses, biomarkers were evaluated as binary variables: quartiles for biomarker concentrations were calculated, and for WBC, urea, and C-reactive protein, the upper quartile was used as cut-off, while the lower quartile was used as cut-off for hemoglobin, sodium, and albumin. Variables with \( p < 0.1 \) in the univariate analyses were included in the multivariate analysis. A risk-stratification tool was derived by dividing patients into groups based on the summarized number of independent risk factors of readmission. Corresponding cumulative incidence curves and hazard ratios were generated.

Two sensitivity analyses were performed: In the first sensitivity analysis, the variable assessing the combined burden of co-morbidities was replaced with individual co-morbidities in the multivariate analysis. In the second sensitivity analysis, the multivariate analysis was restricted to patients, who had a valid measurement of biomarkers within 3 days of discharge. All \( p \) values were two-sided and significance levels were \(< 0.05\). All analyses were performed in SAS Enterprise Guide 7.1.

Outcomes

The outcome measure was all-cause, unplanned readmission within 30 days after discharge from the index-hospitalization. The days from discharge to readmission and the cause of readmission were registered. Further, it was registered if patients died in the follow-up period without a preceding readmission. Patients with multiple readmissions were registered with reference to the first readmission. Data on outcome were collected from medical records, which via linkages to The Danish National Patient Register and The Danish Civil Registration System hold information on all public hospitalizations and mortality [16].

Statistical analyses

As all continuous variables were skewed, median and interquartile range (IQR) was reported. Differences in median values were tested by the non-parametric Wilcoxon rank-sum test. Counts and percentages were reported for categorical variables. Differences between categorical variables were tested with Person’s test or Fisher’s exact test, as appropriate.

To account for competing risk in form of death without a preceding readmission, a regression model proposed by Fine and Gray [17] was used to calculate sub-distributed hazard ratios for variables based on the cumulative incidence function of readmissions. Data was censored at 30 days after discharge. In the regression analyses, biomarkers were evaluated as binary variables: quartiles for biomarker concentrations were calculated, and for WBC, urea, and C-reactive protein, the upper quartile was used as cut-off, while the lower quartile was used as cut-off for hemoglobin, sodium, and albumin. Variables with \( p < 0.1 \) in the univariate analyses were included in the multivariate analysis. A risk-stratification tool was derived by dividing patients into groups based on the summarized number of independent risk factors of readmission. Corresponding cumulative incidence curves and hazard ratios were generated.
Data availability The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Results

Study population

Of the 1320 patients in the CAP-NORTH Cohort, 111 (8.4%) died during the initial hospitalization, 8 (0.6%) were lost to follow-up, and 52 (3.9%) had missing data on biomarkers at discharge (Fig. 1) [12]. These patients were excluded. Thus, the total study population consisted of 1149 patients, who were discharged alive. Patients who were excluded due to missing data on biomarkers were hospitalized and received intravenous (I.V.) antibiotics for a shorter period than the study population (median length of I.V. antibiotic treatment 1 day (IQR, 0–3) vs. 3 days (IQR, 2–6), \( p < 0.001 \) and median length of stay 1.5 days (IQR, 1–4.5) vs. 5 days (IQR, 3–9), \( p < 0.001 \)). No other differences in baseline characteristics or outcomes were observed (Appendix, Table 1).

Baseline characteristics

The median age of the study population was 70 years (IQR, 57–81), 40.6% had no record of co-morbidities, 35.7% had 1 co-morbidity, and 23.7% had \( \geq 2 \) (Table 1). Based on the CURB-65 score, 15.7% of the patients had a severe pneumonia at admission (more than 2 points). The median length of stay of the index-hospitalization was 5 days (IQR, 3–9), and the median length of treatment with I.V. antibiotics was 3 days (IQR, 2–6).

Among 952 patients, where a microbiological test was performed, 217 (22.8%) had a pathogen detected (Table 2). The two most common pathogens were *Streptococcus pneumoniae* (\( n = 61, 6.4\% \)) and *Haemophilus influenzae* (\( n = 55, 5.8\% \)).

Outcomes

One hundred eighty-four (16.0%) patients were readmitted within 30 days after discharge and 27 (2.3%) died without a preceding readmission. A total of 56 (4.9%) patients died within the 30-day follow-up period. Pneumonia was the most common cause of readmission accounting for 35.2% of all readmissions (Table 3). Other frequent causes of readmission were pulmonary and cardiovascular diseases, which accounted for 12.5 and 12.0%, respectively.

Biomarker concentrations at discharge

Patients who were readmitted had higher median WBC concentrations (9.4 vs 8.4 cells × 10⁹/L, \( p < 0.001 \)) and median urea concentrations (5.4 vs. 4.6 mmol/L, \( p = 0.001 \)) and lower...
median albumin concentrations (35 vs 36 g/L, \( p < 0.001 \)) than patients who were not readmitted (Table 4). Patients were divided into binary groups based on biomarker concentrations, with cut-offs corresponding to the upper quartile for WBC, urea, and C-reactive protein and the lower quartile for hemoglobin, sodium, and albumin. Quartile-based cut-offs were hemoglobin < 7.0 mmol/L, WBC \( \geq 10.6 \) cells \( \times 10^9 \)/L, urea \( \geq 7.0 \) mmol/L, sodium < 137 mmol/L, albumin < 32 g/L, and CRP \( \geq 70 \) mg/L.

### Table 1 Baseline characteristics of the study population

| Baseline characteristic          | Study population (N = 1149) |
|---------------------------------|-----------------------------|
| **Demographic factor**          |                             |
| Age, year, median (IQR)         | 70 (57–81)                  |
| Sex, male                       | 537 (46.7)                  |
| Nursing home residency          | 110 (9.6)                   |
| Active smoker                   | 296 (27.8)                  |
| **Co-morbidities**              |                             |
| Number co-morbidities           |                             |
| 0                               | 462 (40.6)                  |
| 1                               | 407 (35.7)                  |
| \( \geq 2 \)                     | 270 (23.7)                  |
| Malignancy                      | 99 (8.6)                    |
| COPD                            | 208 (18.3)                  |
| Other chronic respiratory disease| 138 (12.1)                  |
| Chronic heart failure           | 90 (7.9)                    |
| Other chronic heart disease     | 174 (15.2)                  |
| Chronic liver disease           | 9 (0.8)                     |
| Chronic kidney disease          | 39 (3.4)                    |
| Cerebrovascular disease         | 109 (9.5)                   |
| Other chronic neurological disease| 44 (3.8)                  |
| Diabetes mellitus               | 142 (12.2)                  |
| Severity of pneumonia at admission |            |
| CURB-65 score                   |                             |
| 0–1                             | 559 (55.9)                  |
| 2                               | 284 (28.4)                  |
| 3–5                             | 157 (15.7)                  |
| Course of hospitalization       |                             |
| Length of I.V. antibiotics, d, median (IQR) | 3 (2–6)                      |
| Length of stay, day, median (IQR) | 5 (3–9)                    |
| ICU admittance                  | 80 (7.0)                    |

**Other chronic respiratory diseases** were asthma, bronchiectasis, pulmonary fibrosis, sarcoidosis, sleep apnea. Chronic cardiac diseases were cardiac arrhythmia, ischemic heart disease, and cardiomyopathy. Other chronic neurological diseases were epilepsy, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis. All variables had less than 1% missing values except CURB-65 score (13.0%) and active smoker (7.3%). All variables are reported as numbers and percentages unless otherwise stated.

IQR interquartile range. COPD chronic obstructive pulmonary disease, I.V. intravenous, ICU intensive care unit.

### Table 2 Etiology by study population and tested population

| Pathogen                     | Number | Percentage of study population (N = 1149) | Percentage of tested population (N = 952) |
|------------------------------|--------|------------------------------------------|------------------------------------------|
| Streptococcus pneumoniae     | 61     | 5.3                                      | 6.4                                      |
| Haemophilus influenzae       | 55     | 4.8                                      | 5.8                                      |
| Mycoplasma pneumoniae        | 35     | 3.0                                      | 3.7                                      |
| Moraxella catarrhalis        | 19     | 1.7                                      | 2.0                                      |
| Staphylococcus aureus        | 8      | 0.7                                      | 0.8                                      |
| Pseudomonas aeruginosa       | 11     | 1.0                                      | 1.2                                      |
| Escherichia coli             | 8      | 0.7                                      | 0.8                                      |
| Legionella pneumophila       | 5      | 0.4                                      | 0.5                                      |
| Others                       | 15     | 1.3                                      | 1.6                                      |
| Total                        | 217    | 18.9                                     | 22.8                                     |

### Risk factors of readmission

In the univariate analyses WBC, urea, and albumin were significantly associated with readmission (Table 5). Hazard ratios were 1.67; 95% CI, 1.23–2.25 for patients with WBC \( \geq 10.6 \) cells \( \times 10^9 \)/L or urea \( \geq 7.0 \) mmol/L. For patients with albumin < 32 g/L, the hazard ratio was 1.74; 95% CI, 1.28–2.36. Cumulative incidence curves of biomarkers are plotted in Fig. 2.

In the multivariate analysis, the associations remained significant for WBC and albumin with hazard ratios of 1.50; 95% CI, 1.07–2.11 and 1.78; 95% CI, 1.24–2.54, respectively (Table 5). The only baseline characteristic that was independently associated with readmissions was the combined burden of co-morbidities. The hazard ratio was 1.74; 95% CI, 1.15–2.64 for patients with \( \geq 2 \) co-morbidities compared to patients without co-morbidities.

In order to identify a combined risk-stratification tool, we assessed the combined risk of all independent risk factors. Figure 3 shows the cumulative risk-stratification tool, with patients without risk factors as the reference group (\( n = 509 \)), were 1.76; 95% CI, 1.07–2.11 and 1.78; 95% CI, 1.24–2.54, respectively (Table 5). The only baseline characteristic that was independently associated with readmissions was the combined burden of co-morbidities. The hazard ratio was 1.74; 95% CI, 1.15–2.64 for patients with \( \geq 2 \) co-morbidities compared to patients without co-morbidities.

In order to identify a combined risk-stratification tool, we assessed the combined risk of all independent risk factors. Figure 3 shows the cumulative risk-stratification tool, with patients without risk factors as the reference group (\( n = 509 \)), were 1.76; 95% CI, 1.07–2.11 and 1.78; 95% CI, 1.24–2.54, respectively (Table 5). The only baseline characteristic that was independently associated with readmissions was the combined burden of co-morbidities. The hazard ratio was 1.74; 95% CI, 1.15–2.64 for patients with \( \geq 2 \) co-morbidities compared to patients without co-morbidities.

### Sensitivity analyses

Replacing the variable assessing the combined burden of co-morbidities with individual co-morbidities in the multivariate model did not change the associations between WBC (hazard ratio 1.53; 95% CI, 1.09–2.16) and albumin (hazard ratio...
1.82; 95% CI, 1.28–2.60) and readmission (Appendix, Table 2). Of note, COPD and other neurological diseases were significantly associated with readmission (hazard ratios 1.61; 95% CI, 1.12–2.30 and 2.69; 95% CI, 1.49–4.85, respectively).

The percentages of patients with a measurement of hemoglobin, WBC, urea, sodium, albumin, and C-reactive protein within 3 days before discharge were 86.2, 93.6, 85.0, 88.1, 69.7, and 93.4, respectively. No changes of hazard ratios of WBC (1.78; 95% CI, 1.17–2.30) or albumin (1.87; 95% CI, 1.17–2.98) were observed when the multivariate analysis was restricted to the subset of patients (n = 754, 65.6%), where all biomarkers were measured within 3 days before discharge (Appendix, Table 3).

### Discussion

In this retrospective, multi-center, cohort study of 1149 patients discharged after hospitalization for CAP, we found that WBC ≥ 10.6 cells × 10⁹/L and albumin < 32 g/L at discharge and the presence of ≥ 2 co-morbidities are independent risk factors of 30-day readmission. Further, when WBC, albumin, and co-morbidities were combined into a risk-stratification tool, we found a step-wise increase in risk of readmission according to the number of risk factors.

Previous research on identification of risk factors of readmission after hospitalization for CAP is limited and factors which primarily have been evaluated either pre-exist the pneumonia or reflect the severity at the day of admission. Apart from the presence of co-morbidities, which throughout the literature are found to be an independent risk factor readmission, other frequently evaluated factors, such demographic characteristics and the initial severity of the pneumonia, are not consistently found to be associated with readmission [7–12]. To the best of our knowledge, this study is the first to both evaluate and demonstrate associations between albumin and WBC at discharge and readmission after CAP. Biomarkers at discharge may reflect the health status of patients during a period of recovery and could provide additional information on the risk of readmission besides what can be obtained at the day of admission. Correspondingly, some studies in different patient populations, have found that risk-stratification tools of readmission are improved when data from the entire hospital stay are added to data from the first day of hospitalization [18, 19]. Length of hospitalization, duration of antibiotic treatment, and signs of clinical instability at discharge, which also relate to the health status beyond the day of admission, are, however, not consistently found to be predictive of readmissions after hospitalization for CAP [7–12].

As elevated WBC and depressed albumin are common findings during acute infections, our results could reflect that some patients were discharged too early from the hospital with an on-going pneumonia. Unfortunately, clinical parameters beyond the day of admission were not available in the CAP-NORTH Cohort, and thus, we could not review whether these patients also had clinical signs of active infection at discharge. There are, however, some indications that treatment and discharge patterns in our study were not different from other studies. First, with a median and IQR of WBC at discharge of 8.6 and 6.9–10.6 cells × 10⁹/L, results from our study was very similar to results from another study of patients with CAP and thus, we could not review whether these patients also had clinical signs of active infection at discharge.

### Table 3 Causes of readmission

| Cause of readmission | Number (%) |
|----------------------|------------|
| Pneumonia            | 65 (35.2)  |
| Pulmonary            | 23 (12.5)  |
| Cardiovascular       | 22 (12.0)  |
| Infection            | 20 (10.9)  |
| Malignant            | 11 (6.0)   |
| Surgical             | 8 (4.3)    |
| Neurological         | 6 (3.3)    |
| Other                | 29 (15.8)  |
| Total                | 184 (100)  |

### Table 4 Biomarker concentrations at discharge

| Biomarker at discharge | All (N = 1149) | Not readmitteda (N = 938) | Readmitted (N = 184) | p value |
|------------------------|----------------|---------------------------|----------------------|---------|
| Hemoglobin, mmol/L     | 7.7 (7.0–8.3)  | 7.7 (7.0–8.3)              | 7.6 (7.0–8.3)        | 0.324   |
| WBC, cells × 10⁹/L     | 8.6 (6.9–10.6) | 8.4 (6.7–10.4)             | 9.4 (7.7–11.8)       | < 0.001 |
| Urea, mmol/L           | 4.7 (3.5–7.0)  | 4.6 (3.4–6.6)              | 5.4 (3.7–8.3)        | 0.001   |
| Sodium, mmol/L         | 139 (137–141)  | 139 (137–141)              | 139 (136–141)        | 0.799   |
| Albumin, g/L           | 35 (32–39)     | 36 (32–39)                 | 35 (30–38)           | < 0.001 |
| C-reactive protein, mg/L| 38 (18–70)   | 38 (18–69)                 | 39 (18–72)           | 0.973   |

All variables are reported as medians and interquartile ranges. p values refer to differences between not readmitted and readmitted patients

mmol/L millimole per liter, WBC white blood cell count, g/L grams per liter, mg/L milligrams per liter

a The 27 patients who died without a preceding readmission are not included in the group of patients not readmitted.
CAP, which reported a median and IQR of WBC at discharge of 8.3 and 6.5–11.0 cells × 10^9/L. Second, in terms of treatment, both the length of hospitalization and the duration of I.V. antibiotic therapy in our study were within international recommendations for treatment of CAP [20]. And third, the outcome in our study, both as the overall readmission rate and the proportion of readmissions caused by pneumonia, were similar to reports from other studies, which would not be expected if patients were discharged too early with an ongoing pneumonia [7–12, 21].

Elevated WBC at discharge could also reflect persistent inflammation rather than active infection. In a study from 2008, Yende et al. [22] reported that high discharge concentrations of the pro-inflammatory marker IL-6 were associated with an increased risk of mortality 3 months after hospitalization for CAP. As the authors also suggested, one possible mechanism could be that a persistent inflammation after acute infections increases the risk of cardiovascular events in the same way as elevated levels of inflammatory markers increase the risk in other populations [23].

In 2013, Krumholz [24] proposed that stressors occurring during hospitalization, such as malnutrition, sleep deprivation, and immobility, increase the vulnerability of patients after discharge, a phenomenon described as a post-hospital syndrome. These factors, and not only pre-existing conditions or the severity of the disease at the day of admission, may significantly affect the risk of readmission. Biomarkers measured at discharge might pose a simple and reliable way to assess some of the impact that hospitalization has on the health status of the patients, and thus be useful in identification of patients in high risk of readmission.

When WBC, albumin, and co-morbidities are combined into a risk-stratification tool, the study population could be divided into four groups with a step-wise increase in risk of readmission. This suggests that the combination of biomarkers at discharge and co-morbidities could be used to identify patients which are in need of post-discharge interventions. There are, however, need for validation in prospective studies.

### Limitations

Our study had some limitations. First, due to the retrospective design of the study, the measurement of biomarkers was part of the routine management of patients. This could have led to

| Variable                        | Unadjusted hazard ratios (95% CI) | p value | Adjusted hazard ratios* (95% CI) | p value |
|---------------------------------|-----------------------------------|---------|----------------------------------|---------|
| **Biomarker at discharge**      |                                   |         |                                  |         |
| Hemoglobin, < 7.0 mmol/L        | 1.12 (0.80–1.56)                  | 0.511   | –                                | –       |
| WBC, ≥ 10.6 cells × 10^9/L      | 1.67 (1.23–2.25)                  | < 0.001 | 1.50 (1.07–2.11)                 | 0.018   |
| Urea, > 7.0 mmol/L              | 1.67 (1.23–2.25)                  | < 0.001 | 1.09 (0.75–1.59)                 | 0.660   |
| Sodium, < 137 mmol/L            | 1.28 (0.93–1.76)                  | 0.137   | –                                | –       |
| Albumin, < 32 g/L               | 1.74 (1.28–2.36)                  | < 0.001 | 1.78 (1.24–2.54)                 | 0.002   |
| C-reactive protein, ≥ 70 mg/L   | 1.06 (0.76–1.48)                  | 0.717   | –                                | –       |
| **Baseline characteristic**     |                                   |         |                                  |         |
| Age, per year                   | 1.02 (1.01–1.03)                  | < 0.001 | 1.01 (1.00–1.02)                 | 0.128   |
| Sex, male                       | 1.40 (1.05–1.87)                  | 0.022   | 1.28 (0.93–1.77)                 | 0.135   |
| Nursing home residency          | 1.55 (1.02–2.34)                  | 0.041   | 1.27 (0.76–2.14)                 | 0.360   |
| Active smoker                   | 0.96 (0.69–1.33)                  | 0.794   | –                                | –       |
| **Number co-morbidities**       |                                   |         |                                  |         |
| 0, reference                    | 1.12 (0.78–1.61)                  | 0.549   | 1.03 (0.69–1.56)                 | 0.875   |
| 1                               | 2.09 (1.48–2.96)                  | < 0.001 | 1.74 (1.15–2.64)                 | 0.009   |
| **CURB-65 score**               |                                   |         |                                  |         |
| 0–1, reference                  |                                   |         |                                  |         |
| 2                               | 2.27 (1.60–3.23)                  | < 0.001 | 1.44 (0.94–2.20)                 | 0.091   |
| 3–5                             | 2.20 (1.44–3.36)                  | < 0.001 | 1.22 (0.72–2.06)                 | 0.452   |
| Length of I.V. antibiotics, per day | 1.03 (1.00–1.05)                | 0.026   | 0.99 (0.94–1.04)                 | 0.661   |
| Length of stay, per day         | 1.02 (1.01–1.03)                  | 0.005   | 1.02 (0.99–1.04)                 | 0.350   |
| ICU admittance                  | 0.68 (0.35–1.34)                  | 0.266   | –                                | –       |

*Due to missing values, a total of 938 patients were used in the multivariate model

mmol/L millimole per liter, WBC white blood cell count, g/L grams per liter, mg/L milligrams per liter, I.V. intravenous, ICU intensive care unit
a selection bias, as 52 patients was excluded due to missing values, and thus, our findings may not be generalized to all patients hospitalized for CAP. The 52 patients who were excluded were hospitalized and received I.V. antibiotics for a shorter period than the study population, but otherwise, no differences in either baseline characteristics or outcomes were observed. Further, in a subset of patients, the last measurement of some biomarkers was performed several days before discharge, which could limit the reproducibility of our results. No changes in associations were, however, observed when the statistical analysis was restricted to patients who had all biomarkers measured within 3 days of discharge. Second, as we were limited to data which could be obtained from patient records, we could not evaluate the effect of some potential risk factors of readmission, including alcohol abuse, clinical stability on discharge, and discharge dispositions. Such factors could potentially confound our results. Third, we cannot account for inappropriate antibiotic treatment, which could be a risk factor for readmission. However, to our knowledge, no previous studies have found that inappropriate antibiotic treatment is associated with increased risk of readmission after CAP. Fourth, this cohort was based on patients hospitalized

Fig. 2 Cumulative incidence curves by biomarker at discharge. Abbreviations: WBC white blood cells, CRP C-reactive protein

Fig. 3 Cumulative incidence curve by number of risk factors. Risk factors were WBC ≥ 10.6 cells × 10^9/L and albumin < 32 g/L at discharge and the presence of ≥ 2 co-morbidities. Due to missing values, a total of 1139 patients were used in the analysis
between January 2011 and July 2012, and both demographic characteristics and guidelines of treatment of pneumonia could have changed since then, which might limit the generalizability of our results.

Strengths

The main strength of this study was that we were able to include all consecutive patients with x-ray-confirmed CAP for a full 18 months, thus reducing the risk of inclusion bias. Further, this study was multi-center, and the three hospitals from where patients were included supported an entire region in Denmark. We also had robust and almost complete data regarding death, readmission, and causes of readmission, due to access The Danish National Patient Register and The Danish Civil Registration System.

Conclusions

In this study, we showed that discharge concentrations of WBC \( \geq 10.6 \text{ cells} \times 10^9/\text{L} \) and albumin < 32 g/L and the presences of \( \geq 2 \) co-morbidities were associated with an increase in risk of 30-day readmission for patients hospitalized for CAP. The combination of biomarkers at discharge and co-morbidities could be used to stratify patients according to risk of readmission, and thus help guide post-discharge interventions. However, due to the retrospective design of this study, our results should be validated.

Acknowledgements The authors acknowledge collaborators in the CAPNETZ STIFTNUNG, the CAPNETZ study group, and the Pneumonia Research Group at Nordsjællands Hospital, including Gudrun Kaldan and Sara Falk Jensen.

Funding The study was supported by a research grant from Nordsjællands Hospital and Danmarks Lungeforenings Fond.

Compliance with ethical standards

Conflict of interest Germot Rohde reports personal fees from Pfizer, Boehringer Ingelheim, Solvay, GSK, Essex Pharma, MSD, and Novartis for lectures including service on speakers’ bureaus outside the submitted work and personal fees from CSL Behring, invited speaker, personal fees from Statens Serum Institute outside the submitted work. The remaining authors declare no conflicts of interest.

Ethical approval This study was approved by the Danish Health and Medicines Authority (3-3013-340/1) and data was stored according to the Danish Data Protection Agency (HIH-2013-017).

Informed consent Danish legislation does not require informed consent for register-based studies.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H et al (2009) New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 64(12):1062–1069
2. Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1):71–79
3. Jain S, Self WH, Wunderink RG, Fakharn S, Bark L, Bramley AM et al (2015) Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373(5):415–427
4. File TM Jr, Marrie TJ (2010) Burden of community-acquired pneumonia in North American adults. Postgrad Med 122(2):130–141
5. Leppin AL, Gionfriddo MR, Kessler M et al (2014) Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials. JAMA Intern Med 174(7):1095–1107
6. Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M et al (2011) Risk prediction models for hospital readmission: a systematic review. JAMA 306(15):1688–1698
7. Adamuz J, Viasus D, Campapicrois–Rodriguez P, Cañavate–Jurado O, Jiménez–Martínez E, Isla P et al (2011) A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. Respir Res 16(7):1119–1126
8. Capelastegui A, España Yandiolap PP, Quintana JM, Bilbao A, Diez R, Pascual S et al (2009) Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest 136(4):1079–1085
9. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ (2008) Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 46(4):550–556
10. Mieck ST, Lang A, Fuller BM, Hampton NB, Kollef MH (2014) Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department. BMC Infect Dis 14(1):1–16
11. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J et al (2013) Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals. Clin Infect Dis 57(3):362–367
12. Vecchiarino P, Bohannon RW, Ferullo J, Maljanian R (2004) Short-term outcomes and their predictors for patients hospitalized with community-acquired pneumonia. Heart Lung J Acute Crit Care 33(5):301–307
13. Dharmarajan K, Krumholz HM (2015) Risk after hospitalization: we have a lot to learn. J Hosp Med 10(2):135–136
14. Engelund GB, Jensen AV, Andersen SB, Petersen PT, Lindhardt BO, von Plessen C et al (2017) Penicillin treatment for patients with community-acquired pneumonia in Denmark: a retrospective cohort study. BMC Pulm Med 17(1):66
15. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58(5):377–382
16. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39(7 suppl):30–33
17. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446): 496–509
18. Nguyen OK, Makam AN, Clark C, Zhang S, Xie B, Velasco F et al (2016) Predicting all-cause readmissions using electronic health record data from the entire hospitalization: model development and comparison. J Hosp Med 11(7):473–480
19. Makam AN, Nguyen OK, Clark C, Zhang S, Xie B, Weinreich M et al (2017) Predicting 30-day pneumonia readmissions using electronic health record data. J Hosp Med 12(4):209–216
20. Community-Acquired Pneumonia [Internet]. European Respiratory Society; 2014. 298 p. Available from: http://erspublications.com/content/9781849840491/9781849840491
21. Aliberti S, Peyrani P, Filardo G, Mirsaeidi M, Amir A, Blasi F et al (2011) Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest 140(2):482–488
22. Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD et al (2008) Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 177(11):1242–1247
23. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K et al (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351(25):2599–2610
24. Krumholz HM (2013) Post-hospital syndrome—an acquired, transient condition of generalized risk. N Engl J Med 368(2):100–102